-
![Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt](/abs-image/US/2023/02/09/US20230045419A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230045419A1
公开(公告)日：2023-02-09
申请号：US17782478
申请日：2020-12-07
Applicant: Pfizer Inc.
Inventor： Gary E. Aspnes , Scott W. Bagley , Wesley Dewitt Clark , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David Andrew Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David Walter Piotrowski , Roger B. Ruggeri
IPC: C07D405/14
Abstract: The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.
-
公开(公告)号：US20210163455A1
公开(公告)日：2021-06-03
申请号：US17171385
申请日：2021-02-09
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07C53/06 , C07C53/10 , C07C215/40 , C07D405/14 , C07D413/14 , C07D471/04
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号：US10676465B2
公开(公告)日：2020-06-09
申请号：US16535616
申请日：2019-08-08
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07D405/14 , C07D471/04 , C07C53/06 , C07C53/10 , C07C215/40 , C07D413/14
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号：US09278953B2
公开(公告)日：2016-03-08
申请号：US14506752
申请日：2014-10-06
Applicant: Pfizer Inc.
Inventor： Kevin Barry Bahnck , David James Edmonds , Kentaro Futatsugi , Esther Cheng Yin Lee , Alan Martin Mathiowetz , Elnaz Menhaji-Klotz , Robert Vernon Stanton
IPC: C07D213/63 , A61K31/44 , C07D401/14
CPC classification number: C07D401/14
Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
Abstract translation: 本文提供前列腺素EP3受体的拮抗剂，制备所述拮抗剂的方法，以及包括向有需要的哺乳动物施用所述拮抗剂的方法。
-
公开(公告)号：US20220213072A1
公开(公告)日：2022-07-07
申请号：US17546207
申请日：2021-12-09
Applicant: Pfizer Inc.
Inventor： Andrew John Bessire , David James Edmonds , David Andrew Griffith , Amit Sumant Kalgutkar , Timothy Frank Ryder
IPC: C07D405/14 , C07D401/14
Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
-
Patent Agency Ranking
公开(公告)号：US10934279B2
公开(公告)日：2021-03-02
申请号：US16436311
申请日：2019-06-10
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07C53/06 , C07C53/10 , C07C215/40 , C07D405/14 , C07D413/14 , C07D471/04
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号：US20190382388A1
公开(公告)日：2019-12-19
申请号：US16535616
申请日：2019-08-08
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07D405/14 , C07C53/10 , C07D471/04 , C07C215/40 , C07C53/06 , C07D413/14
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号：US09738626B2
公开(公告)日：2017-08-22
申请号：US14970930
申请日：2015-12-16
Applicant: Pfizer Inc.
Inventor： Kevin Bahnck , Daniel Canterbury , David James Edmonds , Kentaro Futatsugi , Esther Cheng Yin Lee , Elnaz Menhaji-Klotz , Jana Polivkova , Robert Vernon Stanton
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
-
公开(公告)号：US20160176851A1
公开(公告)日：2016-06-23
申请号：US14970930
申请日：2015-12-16
Applicant: Pfizer Inc.
Inventor： Kevin Bahnck , Daniel Canterbury , David James Edmonds , Kentaro Futatsugi , Esther Cheng Yin Lee , Elnaz Menhaji-Klotz , Jana Polivkova , Robert Vernon Stanton
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
-
公开(公告)号：US12065434B2
公开(公告)日：2024-08-20
申请号：US17546207
申请日：2021-12-09
Applicant: Pfizer Inc.
Inventor： Andrew John Bessire , David James Edmonds , David Andrew Griffith , Amit Sumant Kalgutkar , Timothy Frank Ryder
IPC: C07D405/14 , A61K45/06 , C07D401/14
CPC classification number: C07D405/14 , C07D401/14 , A61K45/06
Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.022 seconds)
